ST. LOUIS, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company’s Niobe® remote magnetic navigation system. Respiratory Compensation is designed to further enhance the quality and accuracy of Ablation History and the automation features of the Niobe system by compensating for respiratory motion during an ablation procedure.
“With the stable focal contact Niobe provides, the latest iteration of Ablation History and Respiratory Compensation creates a more precise representation of where lesion sets are actually being created. I am confident this further improves my ability to create contiguous lesions,” said Peter Weiss, MD of Intermountain Medical Center in Salt Lake City, an early adopter of the software upgrade.
Respiratory motion of the heart during cardiac ablation procedures can affect the quality and accuracy of catheter localization within mapping technologies and the automation capabilities of the Niobe system. Respiratory Compensation corrects this distortion by automatically monitoring the movements of a reference catheter over the respiratory cycle and applying an algorithm, involving both the ablation and reference catheters, to filter out respiratory motion. Calculating the correct position of the ablation catheter over the respiratory cycle provides the physician with clearer ablation information and improves the automatic movement of the ablation catheter to targeted positions.
“This most recent enhancement to our Niobe system further supports physicians in their creation of successful linear lesions, which is key to optimizing clinical outcomes,” added William C. Mills, Stereotaxis Chief Executive Officer. “In addition, as the location data are enhanced to better reflect the actual position of the catheter within the heart chamber, the quality of the input data for future developments around automation features is improved. This latest feature reflects our ongoing focus on innovation to evolve our industry leading automated technologies and produce greater results in efficacy, efficiency, and safety of ablation procedures.”
In 2014, the Company introduced the Ablation History software feature to the Niobe system, which provides a real-time, visual display of the catheter’s power output and duration, giving the physician greater visibility of potential lesion gaps, one of the common failure points to achieving favorable ablation outcomes. More than 8,000 procedures have been performed with the Ablation History tool since its introduction.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
STXS Company Contact: Martin Stammer Chief Financial Officer 314-678-6155 STXS Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 email@example.com